Based on the importance of IL-23/IL-17 axis, Bruton’s tyrosine kinase inhibitors can suppress imiquimod (IMQ)-induced psoriasis-like inflammation in mice through the regulation of IL-23/IL-17A in innate immune cells [17,18]. The gene discussed is IL17A; the disease is psoriasis.